Accès ouvert
2024
erratum
OpenAlex
Jeffrey P. Pearson, Anzalee Khan, Talvinder Bhogal, Helen Wong et autres
The authors regret that in the original report some figures from previous studies are incorrectly given. The correct figures are as follows For "The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 6% (25) with two grade …
gb
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
James Pearson, Adeel Khan, Talvinder Bhogal, Helen Wong et autres
Abstract Background Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with brain metastasis (BM), a group historically with poor outcomes. The prevalence of BMs in patients commencing T-DXd is currently unknown. To date, no direct comparisons have been made of the activity …
gb
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Alexandra Johnson, Sonia Bathla, Leena Chagla, Joanne Cliff et autres
Abstract Background: The 21-gene breast cancer (BC) assay (Oncotype Dx) is used to predict chemotherapy benefit in ER+, HER-2- lymph node (LN) negative BC. The RxPONDER trial demonstrated that post-menopausal patients with ER+, HER2- BC with 1-3 LN and a recurrence score …
gb, ca
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Jeffrey P. Pearson, Anzalee Khan, Talvinder Bhogal, Helen Wong et autres
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with brain metastasis (BM), a group historically with poor outcomes. The prevalence of BMs in patients commencing T-DXd is currently unknown. No direct comparisons have been made of the activity of T-DXd in …
gb
(code pays fourni par la source)
Accès ouvert
2023
erratum
OpenAlex
Laurence McEvoy, Joanne Cliff, Daniel F. Carr, Andrea Jorgensen et autres
[This corrects the article DOI: 10.3389/fphar.2023.1178421.].
gb
(code pays fourni par la source)
Accès ouvert
2023
review
OpenAlex
Laurence McEvoy, Joanne Cliff, Daniel F. Carr, Andrea Jorgensen et autres
Background: Taxane-induced peripheral neuropathy (TIPN) is an important cause of premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality of life and survivorship in affected patients. Genetic polymorphisms in the CYP3A family have been investigated but the findings have …
gb
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Benjamin Hall, Ajay Ashok Bhojwani, Helen Wong, Andrea Law et autres
Background: Randomized studies of neoadjuvant (NA) trastuzumab and pertuzumab combined with chemotherapy for HER2-positive breast cancers (BC) have reported pathological complete response (pCR) rates of 39 to 61%. This study aimed to determine the real-world efficacy and toxicity of NA trastuzumab and …
gb
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi et autres
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is …
gb, ch, ca
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Benjamin Hall, Ajay Ashok Bhojwani, Helen Innes, Eliyaz Ahmed et autres
e12108 Background: Neoadjuvant (NA) HER2 blockade with trastuzumab (T) and pertuzumab (P) results in pathological complete response (pCR) rates of 39% to 62%. Diarrhoea is reported in up to 73% of cases. No real-world studies have explored the efficacy and toxicity of …
gb
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Ajay Ashok Bhojwani, Helen Flint, Benjamin Hall, Helen Wong et autres
e12559 Background: Platinum based regimens in the neoadjuvant (NA) setting for triple negative breast cancer (TNBC) have resulted in a significant increase in the pathological response (pCR) rate but at the cost of worse hematological toxicities. Despite these data such NA regimens …
gb
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Ajay Ashok Bhojwani, Helen Flint, Benjamin Hall, Han Hsi Wong et autres
Abstract Background: Palbociclib plus endocrine therapy (ET) significantly increases progression free survival compared to ET alone. Within PALOMA2 neutropenia was the most common AE and reason for dose reductions. No real data exists regarding dose reductions (DRs), dose interruptions (DIs), toxicities and …
gb
(code pays fourni par la source)
2019
conference-abstract
OpenAlex
Benjamin Hall, Ajay Ashok Bhojwani, H Innes, Elham Ahmed et autres
Abstract Background: Studies of neoadjuvant (NA) dual HER2 blockade with trastuzumab (T) and pertuzumab (P) in combination with chemotherapy (CT) for early breast cancer (BC) have reported pathological complete response (pCR) rates of 39 to 62%. These studies also report manageable toxicity …
gb
(code pays fourni par la source)